Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
出版年份 2021 全文链接
标题
Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-02-18
DOI
10.1016/j.annonc.2021.02.004
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Single cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment
- (2020) Anuja Sathe et al. CLINICAL CANCER RESEARCH
- EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study.
- (2020) Elizabeth Catherine Smyth et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
- (2020) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer
- (2020) Takaomi Hagi et al. BRITISH JOURNAL OF CANCER
- The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target
- (2020) V. Gambardella et al. CANCER TREATMENT REVIEWS
- Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
- (2020) Gabriel S Krigsfeld et al. JOURNAL OF CLINICAL PATHOLOGY
- Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
- (2020) Akihito Kawazoe et al. LANCET ONCOLOGY
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
- (2020) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy
- (2020) Katherine I Zhou et al. CLINICAL CANCER RESEARCH
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
- (2020) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
- (2019) R Sundar et al. ANNALS OF ONCOLOGY
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
- (2019) Yung-Jue Bang et al. Future Oncology
- A C-X-C chemokine receptor type 2-dominated crosstalk between tumor cells and macrophages drives gastric cancer metastasis
- (2019) Zhijun Zhou et al. CLINICAL CANCER RESEARCH
- Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma
- (2019) V Gambardella et al. ANNALS OF ONCOLOGY
- Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.
- (2019) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
- (2019) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial
- (2019) Yasuhide Yamada et al. Lancet Gastroenterology & Hepatology
- Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
- (2019) Andrea Necchi et al. EUROPEAN UROLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
- (2019) Sylvie Lantuejoul et al. Journal of Thoracic Oncology
- Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients
- (2018) Michael Davidson et al. Clinical Colorectal Cancer
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
- (2018) Mohamed E. Salem et al. MOLECULAR CANCER RESEARCH
- Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
- (2018) Valentina Fanotto et al. ONCOLOGIST
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- (2018) Y -J Bang et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
- (2018) N Boku et al. ANNALS OF ONCOLOGY
- A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies
- (2018) Cory Batenchuk et al. JOURNAL OF CLINICAL PATHOLOGY
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET ONCOLOGY
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) F. Lordick et al. ANNALS OF ONCOLOGY
- Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data
- (2015) Lisa M. Hess et al. Gastric Cancer
- FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
- (2014) X Su et al. BRITISH JOURNAL OF CANCER
- Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
- (2014) Suling J Lin et al. GUT
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
- (2013) N C T van Grieken et al. BRITISH JOURNAL OF CANCER
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis
- (2012) A. M. Dulak et al. CANCER RESEARCH
- E-cadherin dysfunction in gastric cancer - Cellular consequences, clinical applications and open questions
- (2012) Patrícia Carneiro et al. FEBS LETTERS
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started